12:00 AM
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ibrutinib: Phase II started

Pharmacyclics enrolled the fifth patient in the open-label, international Phase II SPARK trial evaluating 560 mg once-daily oral ibrutinib in about 110 MCL patients who have received >=1 prior rituximab-containing chemotherapy regimen and who have progressed after bortezomib therapy. The enrollment triggered a $50 million milestone payment to Pharmacyclics from Johnson & Johnson's Janssen Biotech Inc. unit under a...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >